Detailed Information

Cited 20 time in webofscience Cited 22 time in scopus
Metadata Downloads

Generation of bioactive MSC-EVs for bone tissue regeneration by tauroursodeoxycholic acid treatmentopen access

Authors
Cha, Kyung-YupCho, WoongjinPark, SunghyunAhn, JinsungPark, HyoeunBaek, InhoLee, MinjuLee, SunjunArai, YoshieLee, Soo-Hong
Issue Date
Feb-2023
Publisher
ELSEVIER
Keywords
Mesenchymal stem cell-derived extracellular; vesicles (MSC-EVs); Tauroursodeoxycholic acid (TUDCA); Anti-inflammation; Osteogenic differentiation; Bone regeneration
Citation
Journal of Controlled Release, v.354, pp 45 - 56
Pages
12
Indexed
SCIE
SCOPUS
Journal Title
Journal of Controlled Release
Volume
354
Start Page
45
End Page
56
URI
https://scholarworks.dongguk.edu/handle/sw.dongguk/21326
DOI
10.1016/j.jconrel.2022.12.053
ISSN
0168-3659
1873-4995
Abstract
Extracellular vesicles (EVs) are nano-sized carriers that reflect the parent cell's information and are known to mediate cell-cell communication. In order to overcome the disadvantages of mesenchymal stem cells (MSCs) in cell therapy, such as unexpected differentiation leading to tumorization, immune rejection, and other side ef-fects, EVs derived from MSCs (MSC-EVs) with the tissue regenerative function have been studied as new cell-free therapeutics. However, therapeutic applications of EVs require overcoming several challenges. First, the pro-duction efficiency of MSC-EVs should be increased at least as much as the quantity of them are required to their clinical application; second, MSC-EVs needs to show various functionality further, thereby increasing tissue regeneration efficiency. In this study, we treated tauroursodeoxycholic acid (TUDCA), a biological derivative known to regulate cholesterol, to MSCs and investigated whether TUDCA treatment would be able to increase EV production efficiency and tissue regenerative capacity of EVs. Indeed, it appears that TUDCA priming to MSC increases the yield of MSC-EVs >2 times by reducing the cellular cholesterol level in MSCs and increasing the exocytosis-related CAV1 expression. Interestingly, it was found that the EVs derived from TUDCA-primed MSCs (T-EV) contained higher amounts of anti-inflammatory cytokines (IL1RN, IL6, IL10, and IL11) and osteogenic proteins (ALP, RUNX2, BMP2, BMPR1, and BMPR2) than those in control MSC-EVs (C-EV). Besides, it was shown that T-EV not only regulated M1/M2 macrophages differentiation of monocytes, also effectively increased the osteogenic differentiation of MSCs as well as bone tissue regeneration in a bone defect rat model. Based on these results, it is concluded that TUDCA treatment to MSC as a new approach endows EV with high-yield production and functionality. Thus, we strongly believe T-EV would be a powerful therapeutic material for bone tissue regeneration and potentially could be expanded to other types of tissue regeneration for clinical applications.
Files in This Item
There are no files associated with this item.
Appears in
Collections
College of Life Science and Biotechnology > Department of Biomedical Engineering > 1. Journal Articles

qrcode

Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.

Related Researcher

Researcher Lee, Soo Hong photo

Lee, Soo Hong
College of Life Science and Biotechnology (Department of Biomedical Engineering)
Read more

Altmetrics

Total Views & Downloads

BROWSE